TNP
SIGMA/T3955 - ≥95% (HPLC)
Synonym: N2-
CAS Number: 519178-28-0
Empirical Formula (Hill Notation): C20H16F3N7O2
Molecular Weight: 443.38
MDL Number: MFCD16875436
Linear Formula: C20H16F3N7O2
Product Type: Chemical
This picture is provided solely for illustration purposes, it may have been created or edited with AI. Optical properties of the actual product may deviate. Relevant product information is printed on labeled products and other accompanying or available information material.
This image depicts T3955-25MG.
This image depicts T3955-25MG.
| assay | ≥95% (HPLC) |
| color | yellow |
| form | powder |
| InChI | 1S/C20H16F3N7O2/c21-20(22 |
| InChI key | DDSBPUYZPWNNGH-UHFFFAOYSA |
| originator | Novartis |
| Quality Level | 100  |
| SMILES string | [O-][N+](=O)c1ccc(CNc2nc( |
| solubility | DMSO: ≥10 mg/mL |
| storage condition | protect from light |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | Potent and selective IP6K inhibitor; less selective inhibitor of IP3K. |
| Biochem/physiol Actions: | TNP is a potent and selective IP6K inhibitor; less selective inhibitor of IP3K. Discovery of TNP as an inositol trisphosphate (IP3) kinase inhibitor was first reported in 2002, However, a recent reference shows that TNP is more potent as an IP6K inhibitor, making it valuable for study of inositol pyrophosphates. |
| Features and Benefits: | This compound was developed by Novartis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Preparation Note: | TNP is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml. |
| Hazard Codes | T |
| Risk Statements | 25-36 |
| Safety Statements | 26-45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥95% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |